OP38 Managed (Early) Access In England: The ‘Ins And Outs’

Introduction Managed access approaches have been used by The National Institute for Health and Care Excellence (NICE) in partnership with NHS England since 2015. Cancer Drugs Fund is an exemplar of this approach which enables earlier patient to promising new treatments while further real-world data collected address evidential uncertainties. Increasingly, being applied rare diseases other conditions unmet clinical need extensive involvement from organizations clinicians. Methods All Access Agreements (MAAs) development or published were reviewed present on the number technologies (i) entering, (ii) active monitoring, (iii) exiting managed access, both cancer disease areas. Results After six years first MAA (at December 2021), over 73,000 patients benefited cancer, genetic diseases, including cystic fibrosis, spinal muscular atrophy sickle cell via access. Fifty-eight commissioned access: thirty collection, eleven re-evaluated, seventeen exited Patient engagement essential successful collections delivered underway. Conclusions providing that would not otherwise be recommended use England. maturing at same time volume topics entering expected grow throughout 2022 introduction Innovative Medicines Fund.